Skip to main content

Advertisement

Neuroendocrine carcinoma arising in soft tissue: three case reports and literature review

Abstract

Background

Neuroendocrine tumours (NET) are tumours arising from neuroendocrine cells of neural crest origin. They are characterised by the presence of neurosecretory granules which react positively to silver stains and to specific markers including neuron specific enolase, synaptophysin and chromogranin. Metastasis to the skin occurs infrequently but primary soft tissue NET is excessively rare.

Case presentation

We report our experience with 3 such cases. In the first case, the NET originated in muscle and was treated with wide surgical excision and adjuvant radiotherapy. The second case presented as a subcutaneous mass in the foot and the tumour was positive on 123I mIBG scan. She has had prolonged recurrence-free survival following primary hypo-fractionated radiotherapy. In the third case, a cutaneous nodule proved to be a NET and at surgery, lymph node disease was present. He has remained disease-free after surgical excision without the need for external beam radiotherapy.

Conclusion

These tumours appear to have a good prognosis. Complete excision offers potentially curative treatment. Adjuvant radiotherapy may be helpful when the tumour margin is narrow. For patients with unresectable disease or where surgery would not be appropriate, radiotherapy appears to be an effective therapeutic option.

Background

Neuroendocrine tumours (NET) most commonly originate in the appendix, small intestine, rectum and bronchus [1, 2]. The majority are of low-grade malignant potential with an indolent course and can be termed "carcinoids". The release of 5-HT and other vasoactive substances into the systemic circulation gives rise to the "carcinoid syndrome", consisting of flushing, wheezing, diarrhoea and eventually right-sided valvular heart disease [3]. This syndrome is usually associated with bulky liver metastases. Metastasis to skin has been reported but typically occurs in association with metastases elsewhere [4, 5]. NET arising de novo in the skin are very rare and there are no reports of these tumours originating in soft tissues. We describe our experience of three cases.

Case presentation

Case 1

A 43 year old man presented with a four month history of a slowly growing hard mass in his right upper thigh. He had no systemic symptoms such as flushing, diarrhoea or wheeze. A 3 × 3 cm mass was excised and found to have arisen in the right sartorius muscle extending into the rectus femoris and vastus medialis. Histopathology revealed skeletal muscle and subcutaneous tissues infiltrated by polygonal cells containing neurosecretory granules (Figures 1a and 1b). Immunohistochemistry showed strong and diffuse positivity for synaptophysin, chromogranin (Figure 1c), cytokeratin (Figure 1d) Bcl-2 protein and neuron-specific enolase (NSE) but negativity for S100, desmin and epithelial membrane antigen (EMA). Electron microscopy showed polygonal cells with deeply indented nuclei and neurosecretory granules in the cytoplasm. These appearances were consistent with a neuroendocrine carcinoma. 24 hour urine 5HIAA concentration was elevated at 92 mmol (normal: 9–31 nmol/24 h).

Figure 1
figure1

(a) Rows of cells divided by fine fibrovascular stroma into a packet arrangement. This arrangement is typical of an endocrine tumour (H&E × 10). (b) Fine stroma with relatively uniform-looking cells and nuclear irregularity. The nuclear irregularity suggests that the tumour is not benign (H&E × 40). (c) High power showing granular cytoplasmic staining with anti-chromogranin antibody. (d) High power showing diffuse cytoplasmic staining with anti-cytokeratin antibody

No tumour was demonstrated elsewhere: mIBG and octreotide scans were negative as were CT scans of thorax, abdomen and pelvis.

Following excision he was treated with adjuvant radical dose external beam radiotherapy to the thigh in view of the depth of invasion of the tumour and its poor histological features. Following treatment his 5HIAA concentrations normalised and he remains free of relapse, five years later.

Case 2

A 79 year frail old lady presented with a lump on the sole of the right foot which had gradually increased in size over the previous nine months. The right leg had gradually become more swollen and painful. She had not experienced flushing attacks or diarrhoea. On examination there was a hard subcutaneous mass on the plantar surface of the right foot involving the metatarsal heads with associated erythema and thinning of the skin. The entire right leg was swollen with lymphoedema.

A magnetic resonance (MR) scan was performed of the right foot (Figure 2). This revealed a 7 × 5 cm mass involving skin, flexor compartment of the right sole and flexor tendons. Core biopsy was performed for tissue diagnosis. The appearance was of a necrotic tumour with pleomorphic epithelioid cells. Immunohistochemical staining showed that the cells expressed neuroendocrine markers (synaptophysin, chromogranin, NSE) and cytokeratin marker (CAM 5.2) but were negative for S100, HMB45, CD99 and CD117. The appearances were consistent with a neuroendocrine tumour.

Figure 2
figure2

MRI of the right foot in Case 2. A 7 × 5 cm mass is present involving the skin and flexor tendons.

A 123I mIBG (meta-iodobenzylguanidine) scan revealed increased uptake into the tumour consistent with its neuroendocrine origin (Figure 3).

Figure 3
figure3

4 hour 123I mIBG scan of both feet in Case 2. There is increased uptake of radionucleotide corresponding to the lesion on MRI.

CT scans of the chest, abdomen and pelvis showed metastatic lymph node enlargement in the right groin and pelvic side wall but no pathology in the liver or lungs.

Radical surgery was not possible because of the extent of tumour and the patient's general condition. Uptake of mIBG was deemed inadequate to contemplate curative treatment with a therapeutic dose of 131I mIBG. Instead, the patient was treated with external beam radiotherapy to the right foot (using 20 MeV electron beam) and to the right side of the pelvis (with parallel pairs of photons). The tumour dose was 30 Gy in 5 fractions with treatment given over 4 weeks (6 Gy once weekly).

MR scanning 10 months later revealed significant reduction in tumour size (3 × 1.5 cm) and no residual pelvic side-wall or inguinal disease. When last reviewed she was well with no cancer-related symptoms. The nodule on the sole of the right foot had not changed over 55 months follow-up and the lymphoedema had completely resolved.

Case 3

A 61 year old retired civil servant was noted to have a swelling over the left iliac crest. Fourteen months previously he had undergone wide local excision and local radiotherapy for a high grade spindle cell sarcoma affecting the lower left leg. The site was well-healed with no evidence of recurrence. At follow-up, a 2 cm cutaneous nodule was noted over the left iliac crest; it was fleshy and smooth in consistency, being darker than surrounding skin. There were no palpable lymph nodes. He had no systemic symptoms such as flushing or diarrhoea.

Fine needle aspiration cytology (FNAC) of the nodule suggested malignancy. A skin ellipse was resected and included tumour nodules in the deep dermis. Immunohistochemistry showed strong and diffuse positive staining for neuroendocrine markers (NSE, chromogranin, synaptophysin) and CAM 5.2 but was negative for EMA, S100 and HMB45.

Histology was compared with the previous sarcoma but was totally different. Appearances were interpreted as consistent with a neuroendocrine tumour. 24 h urinary 5HIAA concentration was normal. CT scans of thorax, abdomen and pelvis revealed a 1.5 cm inguinal lymph node. FNAC of the node revealed malignant cells. An octreotide scan showed no sign of visceral metastasis or occult primary tumour. A left inguinal dissection was performed; eleven nodes were removed with one showing neuroendocrine tumour differentiation. Surgery was thought to have been complete such that adjuvant radiotherapy was not required. He remains free of recurrence at 79 months follow-up.

Discussion

Skin or soft tissue involvement in NET is rare and may represent either primary cutaneous disease or metastatic spread from primary neuroendocrine disease elsewhere usually in the lung or gastrointestinal tract [6]. There have been seven previously published reports of primary NET arising de novo in the skin but none where the tumour originates in the limbs or soft tissues [712]. Previously reported cases of primary skin NET were on the trunk or scalp and were single nodules ranging from 1–4 cm in diameter. The prognosis of these tumours appears favourable as recurrences are rare after prolonged follow-up (Table 1).

Table 1 Primary cutaneous neuroendocrine tumours

The diagnosis of primary cutaneous or soft tissue NET depends on exclusion of metastases from an occult tumour elsewhere. Unlike in primary skin NET, skin metastases from an occult primary are usually multiple [9]. Since these tumours are slow growing indolent tumours, metastasis tends to be a late manifestation of advanced disease. The primary occult tumour will usually have attained a diameter of at least 1 cm and not infrequently 2 cm particularly when arising in the appendix or rectum [13, 14]. Consequently, the primary tumour is usually large enough for detection by diagnostic imaging. Furthermore, skin metastases from pulmonary or laryngeal NET are usually preceded by symptoms from the primary tumour [15].

Identifying small primary tumours may be difficult with conventional imaging techniques such as ultrasound, CT and MRI [16]. Imaging with 123I mIBG shows a sensitivity and specificity of approximately 60% in identifying neuroendocrine tumours [17]. Since NET usually express somatostatin receptors, scanning with radiolabelled somatostatin analogue (octreotide) is often helpful. Compared with mIBG imaging, octreotide scanning is more sensitive (72–87%) although less specific [18].

The presence of metastases is important prognostically as survival is reduced from 70% at 5 years (without metastases) to less than 50% (with metastases) [2].

Macroscopically, a NET usually appears as a yellow solid tumour because of its high lipid content. Histologically, they are composed of rows of cuboidal eosinophilic cells arranged in trabecular, follicular or glandular patterns. Definitive diagnosis requires specific histochemical and immunohistochemical staining. Markers of neuroendocrine differentiation include neuron-specific enolase, synaptophysin and chromogranin. Keratin staining (including CAM 5.2) is generally concentrated at one edge of the nucleus to give an appearance of "dot-like" keratin positivity. Neurosecretory granules can be seen ultrastructurally.

The differential diagnosis includes primary cutaneous neoplasms arising from neurosecretory cells (Merkel cells) in the skin. These tumours, known as Merkel cell carcinomas (MCC), are composed of uniform cells with scanty neoplasm, round to ovoid nuclei with finely dispersed chromatin, inconspicuous nucleoli and frequent mitotic figures. Small membrane-bound dense granules are seen in MCC at electron microscopy in contrast to NET where granules are often large and irregular. Early reports of neuroendocrine differentiation in MCC utilised silver staining reactions and demonstrated argyrophilia but negative argentaffin reactions [19]. These have largely been superseded by specific stains for neuroendocrine markers such as chromogranin which can be positive in either MCC or NET. Immunohistochemical stains in MCC tumours show variable positivity for cytokeratin and CK20 often in a perinuclear arrangement in contrast to the more diffuse staining seen in NET [20] and in the cases reported here. More recently, distinctive cytogenetic abnormalities have been described in MCC which may help differentiate MCC from NET [21].

Clinically, MCC tumours are characterised by aggressive behaviour with local recurrences, frequent metastases and relatively poor response to conventional therapies [21, 22]. In case 1 the tumour clearly arose from muscle. The tumour in case 2 could have originated in the skin and invaded deeply as the histology showed it to be in the subcutaneous tissue. However, it would have been MCC stage II as the lymph nodes were involved and these tumours have a median survival of only 5 months [23]. Similarly, the long recurrence-free survival in case 3 (also with lymph node disease) makes this unlikely to have been a MCC.

As with previous reports of cutaneous NET, primary surgical excision was the preferred treatment in our cases, combined with nodal clearance in (case 3) or adjuvant radiotherapy (case 1). Excision of a skin NET and lymph node metastasis was successful in a previous case report [12]. Disease control in our patients has been good at long term follow-up.

In case 2, primary hypofractionated radiotherapy was used as radical surgery was not possible. This approach has been used for several other tumours e.g bladder, prostate where patients are frail and cannot tolerate conventionally fractionated radical doses [24]. Radiotherapy has been used successfully to control unresectable NET in the brain, spinal cord and bone [25]. Disease regression and symptom palliation was achieved in the majority of patients.

We believe these cases represent primary NET because no evidence of tumour could be found elsewhere after follow-up of 5 years. In only one patient were urinary 5 H-T metabolites increased and this patient did not experience features of the carcinoid syndrome presumably because the quantity of peptides secreted was too low.

The soft tissue lesions in all our patients had advanced slowly over a period of between 4 to 9 months and had metastasized only to regional lymph nodes and not to distant organs.

In summary, these tumours appear to have a good prognosis. Complete excision offers potentially curative treatment. Staging is required to exclude lymph node or distant metastases. Adjuvant radiotherapy may be helpful when the tumour margin is narrow. Patients with recurrent disease or aggressive histopathological appearances require radical radiotherapy doses. Although potentially beneficial, uptake of mIBG and octreotide is probably insufficient in the majority of cases to deliver tumouricidal doses. For patients with unresectable disease or where surgery would not be appropriate, radiotherapy appears to be an effective therapeutic option.

References

  1. 1.

    Kulke MH, Mayer RJ: Carcinoid tumors. New Eng J Med. 1999, 340: 858-868. 10.1056/NEJM199903183401107.

  2. 2.

    Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumours. Cancer. 1997, 79: 813-829. 10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2.

  3. 3.

    Godwin JD: Carcinoid tumours; an analysis of 2837 cases. Cancer. 1975, 36: 560-569. 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4.

  4. 4.

    Keane J, Fretzin DF, Jao W, Shapiro CM: Bronchial carcinoid metastatic to skin. Light and electron microscopic findings. J Cutan Pathol. 1980, 7: 45-49. 10.1111/j.1600-0560.1980.tb00976.x.

  5. 5.

    Rodriquez G, Villamizar R: Carcinoid tumour with skin metastasis. Am J Dermatopathol. 1992, 3: 263-269.

  6. 6.

    Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet. 1999, 352: 799-905. 10.1016/S0140-6736(98)02286-7.

  7. 7.

    Van Dijk C, Ten-Seldam RE: A possible primary cutaneous carcinoid. Cancer. 1975, 36: 1016-1020. 10.1002/1097-0142(197509)36:3<1016::AID-CNCR2820360326>3.0.CO;2-L.

  8. 8.

    Brody HJ, Stallings WP, Fine RM, Someren A: Carcinoid in an umbilical nodule. Arch Dermatol. 1979, 114: 570-572. 10.1001/archderm.114.4.570.

  9. 9.

    Bart RS, Kamino H, Waisman J, Lindner A, Colen S: Carcinoid tumour of skin: Report of a possible primary case. J Am Acad Dermatol. 1990, 22: 366-370.

  10. 10.

    Smith PA, Chappell RH: Another possible primary carcinoid tumour of skin?. Virchows Arch A Pathol Anat Histopathol. 1995, 409: 99-103.

  11. 11.

    Courville P, Joly P, Thomine E, Ziode J, Soubrane JC, Kuhn JM, Lauret P: Primary cutaneous carcinoid tumour. Histopathology. 2000, 36: 564-572. 10.1046/j.1365-2559.2000.00918-2.x.

  12. 12.

    MacKenzie DN, McCormick CSF, Morris RJ: Lymph node metastasis from a primary skin carcinoid tumour. Br J Plastic Surg. 2003, 56: 718-721. 10.1016/S0007-1226(03)00210-8.

  13. 13.

    Moertel CG, Weiland LH, Nagorney DM, Dockerty MB: Carcinoid of the appendix: treatment and prognosis. N Engl J Med. 1987, 317: 1699-1701.

  14. 14.

    Bates HR: Carcinoid tumors of the rectum: a statistical review. Dis Colon Rectum. 1966, 9: 90-92. 10.1007/BF02617306.

  15. 15.

    Schmidt U, Metz KA, Schrader M, Leder LD: Well differentiated (oncocytoid) neuroendocrine carcinoma of the larynx with multiple skin metastases. Laryngeal Otol. 1994, 108: 272-274.

  16. 16.

    Meko JB, Doherty GM, Siegel BA, Norton JA: Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Surgery. 1996, 120: 975-983. 10.1016/S0039-6060(96)80043-2.

  17. 17.

    Hoefnagel CA: MIBG and radiolabelled octreotide in neuroendocrine tumors. Q J Nucl Med. 1995, 39: 137-139.

  18. 18.

    Kaltas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB: Comparison of somatostatin analogue and meta-iodoguanidine radionucleotides in the diagnosis and localisation of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001, 86: 895-902. 10.1210/jc.86.2.895.

  19. 19.

    Warner TFCS, Uno H, Hafez R, Burgess J, Bolles C, Lloyd RV, Oka M: Merkel cells and Merkel cell tumors. Ultrastructure, immunocytochemistry and review of the literature. Cancer. 1983, 52: 238-245. 10.1002/1097-0142(19830715)52:2<238::AID-CNCR2820520209>3.0.CO;2-W.

  20. 20.

    Welsh NMG: Primary neuroendocrine (Merkel cell) carcinoma of the skin: morphologic diversity and implications thereof. Hum Pathol. 2001, 32: 680-689. 10.1053/hupa.2001.25904.

  21. 21.

    Sibley RK, Dehner LP, Rosaia J: Primary neuroendocrine (Merkel cell) carcinoma of the skin. A clinicopathologic and ultrastructural study of 43 cases. Am J Surg Pathol. 1985, 9: 95-108. 10.1097/00000478-198502000-00004.

  22. 22.

    Perlman JP, Lumadue JA, Hawkins AL, Cohen K, Colombani P, Griffin CA: Primary cutaneous neuroendocrine tumors. Cancer Genet Cytogenet. 1995, 82: 30-34. 10.1016/0165-4608(94)00271-C.

  23. 23.

    Savage P, Constenla D, Fisher C, Thomas JM, Gore ME: The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital. Clin Onco. 1997, 9: 164-167. 10.1016/S0936-6555(97)80073-8.

  24. 24.

    Scholten AN, Leer JW, Collins CD, Wondergem J, Hermans J, Timothy A: Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol. 1997, 43: 163-169. 10.1016/S0167-8140(96)01893-2.

  25. 25.

    Schupak KD, Wallner KE: The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumours. Int J Radiat Oncol Biol Phys. 1991, 3: 489-499.

  26. 26.

    Collina G, Quarto F, Eusebi V: Trabecular carcinoid of the skin with cellular stroma. Am J Dermatopathol. 1998, 10: 430-435.

Download references

Acknowledgements

Patients' consent was obtained for publication of these case reports

We thank Professor Cyril Fisher for his helpful comments and for providing histological material for this report

Author information

Correspondence to Steve L Hyer.

Additional information

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

SLH preparation of final draft, literature search, corrections and response to reviewers

JM preparation of initial draft, collation of patient information

CLH idea for the study, identification of patients, manuscript preparation and revisions

All authors read and approved final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Authors’ original file for figure 3

Authors’ original file for figure 4

Authors’ original file for figure 5

Authors’ original file for figure 6

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Octreotide
  • Neuroendocrine Tumour
  • Neuroendocrine Carcinoma
  • Merkel Cell Carcinoma
  • Neuroendocrine Marker